Andreas Hochhaus

[Leukemia Journal @LeukemiaJnl]

Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial | Leukemia https://t.co/FAJYbHOLEz

[Andreas Hochhaus @AndreasHochhaus]

@OSUHematology @AkEisfeld @OSUCCC_James Gratulation!

[Jorge Cortes MD @jorgecortesmd]

Final results of asciminib for patients with T315I just published. @uabmedicine @ONealCancerUAB @icmlf @ASH_hematology @DelphineGJRea @AndreasHochhaus @timhughesCML @mjmauroMD https://t.co/4f0JFuYWKC

[Andreas Hochhaus @AndreasHochhaus]

28.5.2026: 25 years TKI in hematology and oncology.
Follow this exciting story in the Leukemia journal.
@LeukemiaJnl @icmlf @cmlnet

[Andreas Hochhaus @AndreasHochhaus]

@jorgecortesmd @uabmedicine @ONealCancerUAB @icmlf @ASH_hematology @BloodGlobalHema Have a good start!

[Leukemia Journal @LeukemiaJnl]

DUX4-rearranged B-ALL: deciphering a biological and clinical conundrum | Leukemia https://t.co/9TgY2YxSu8

[Leukemia Journal @LeukemiaJnl]

New consensus statement!

Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus | Leukemia https://t.co/mZnfL28hnG

[ESH (Haematology) @ESHaematology]

François-Xavier Mahon (Bordeaux) shares results from the ASC4START trial: Asciminib shows superior tolerability vs Nilotinib in newly diagnosed CML-CP — a promising new frontline option.
#ESHCML2025 #ESHCONFERENCES #CMLsm
Chairs @GCC_Cortes · @timhughesCML · Krause

[International CML Foundation @icmlf]

The countdown is over- the ESH-iCMLf 27th Annual John Goldman Conference on CML: Biology and Therapy starts tomorrow!

If you're not able to attend - don't worry, we've got you covered -Follow us for daily highlights and updates

See you in Estoril — or online!

@ESHaematology

[Jorge Cortes MD @jorgecortesmd]

Starting the @ESHaematology @icmlf John Goldman CML meeting in Estoril with top acting abstracts. @GACancerCenter @BloodGlobalHema

[ESH (Haematology) @ESHaematology]

#ESHCML2025: THE PRELIMINARY PROGRAM IS AVAILABLE
Read it now & register➡https://t.co/Q84gZ5sDy5
ESH-#iCMLf 27th John Goldman Conference on #CMLsm
Oct. 10-12, 2025 in Estoril, Portugal
Chairs: @GCC_Cortes @timhughesCML Daniela S. Krause
#ESHCONFERENCES @icmlf #Haematology #CMLsm

[Mostafa Faisal @MostafaFaisal14]

Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblings @LeukemiaJnl https://t.co/3eoEJfx3GM

[International CML Foundation @icmlf]

Join leading minds in CML care and research at the 27th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, held October 10–12 in beautiful Estoril, Portugal.

📍 Estoril, Portugal
🗓️ October 10–12, 2025
🔗 https://t.co/pTGaWO4vgG

[ESH (Haematology) @ESHaematology]

📣#ESHCML2025 PROGRAM HIGHLIGHT:
3 MEET THE EXPERT SESSIONS!
Learn more & register here➡https://t.co/Q84gZ5s5Ix
ESH-#iCMLf 27th John Goldman Conference on #CMLsm
Chairs: @GCC_Cortes @timhughesCML Daniela S. Krause
#ESHCONFERENCES @icmlf

[Saurabh Zanwar @ZanwarSaurabh]

A one stop shop for the current risk stratification schema in plasma cell disorders!

As always, thank you for being so generous with your time @VincentRK! Absolutely wonderful experience learning the art of scientific communication from the very best!

#mmsm #bookmark

[Leukemia Journal @LeukemiaJnl]

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes | Leukemia https://t.co/fo8NxEeAHl

[Leukemia Journal @LeukemiaJnl]

Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera | Leukemia https://t.co/SH5ZKDIZAn

[Leukemia Journal @LeukemiaJnl]

Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL) | Leukemia https://t.co/W8nnI9yfV9

[Andreas Hochhaus @AndreasHochhaus]

Just published:
On behalf of the European LeukemiaNet, an international expert panel led presented the 2025 update of the management recommendations of chronic myeloid leukemia #CML in the journal LEUKEMIA @LeukemiaJnl open access.

https://t.co/m97NicZLcC

[Andreas Hochhaus @AndreasHochhaus]

Just published: on behalf of the European LeukemiaNet, the international expert panel led by Prof Jane Apperley presented the 2025 management recommendations of chronic myeloid leukemia (CML) in LEUKEMIA @LeukemiaJnl open access.

https://t.co/m97NicZLcC